Two scores, two different questions about your knee

Leaving a cartilage appointment with two sets of numbers — a MOCART figure from your MRI report and an IKDC score from your questionnaire — can feel more confusing than reassuring. Both appear in clinical follow-up after knee cartilage repair, and both matter, but they are measuring entirely different things.

The MOCART score is produced from an MRI scan. It rates what the repair tissue actually looks like inside the joint: how completely the defect has filled, how smoothly the surface integrates with surrounding cartilage, and what the signal characteristics of the new tissue suggest about its quality. It tells the radiologist and surgeon something about structure.

The IKDC — the International Knee Documentation Committee Subjective Knee Score — is a questionnaire completed by the patient. On a scale of 0 to 100, it captures symptoms, daily activity, and sport: in short, how the knee feels and functions in real life.

A reassuring MRI does not automatically mean a patient feels well, and a high IKDC does not guarantee that the repair tissue looks perfect on scanning. Understanding what each score is — and is not — asking prevents either result from being misread as the whole picture of recovery.

How ChondroFiller works as an injectable collagen scaffold

ChondroFiller is a CE-marked Class III medical device — not a drug, not a cell therapy, and not a pre-formed implant. Its active material is an acellular Type I collagen hydrogel: a purified structural matrix that contains no living cells of its own.

When introduced into a focal cartilage defect via ultrasound-guided injection at an outpatient appointment, the hydrogel sets in situ, conforming to the contours of the defect. From that point, it acts as a framework that draws the patient's own progenitor cells in from the surrounding tissue — a process termed acellular matrix-induced chondrogenesis. In plain terms: the injection provides the scaffolding; the patient's biology does the building.

Ex vivo laboratory data from femoral condyle specimens support this mechanism directly. By day 14, DNA content within the collagen matrix had risen 2.4-fold compared with baseline, confirming that endogenous cell recruitment is measurable and biologically active within the first fortnight after treatment.

The repair tissue does not reach its final form during those early weeks, however. The scaffold continues to mature over subsequent months as cells migrate, differentiate, and deposit new extracellular matrix. This maturation timeline has a direct bearing on how MOCART scores should be interpreted: an MRI taken at four weeks captures early-stage tissue, not the eventual repair quality — a point the next section examines with specific numbers from ChondroFiller's clinical follow-up data.

IKDC scores — what clinical studies show about knee function

Across four knee-specific clinical studies, ChondroFiller consistently produces IKDC improvements of approximately 30 points over 12 months — nearly double the established Minimal Clinically Important Difference (MCID) of 16.7 points. Below that MCID threshold, patients do not perceive a meaningful change in how their knee performs day to day; a 30-point gain places outcomes well into territory that patients notice.

The timeline of that gain is broadly consistent across study types. In a randomised multicentre trial, IKDC scores improved significantly from pre-operative levels at both 3 and 6 months (p<0.05), with that improvement maintained through to 12 months; no adverse events were reported. A 2024 prospective cohort of 17 patients (mean age 31 years) confirmed the same trajectory: statistically significant gains at 3 months, sustained at 6 and 12 months, with no significant difference between the 6- and 12-month timepoints (p>0.05). In practical terms, recovery appears to consolidate at a high level by 6 months rather than continuing to climb or sliding back — the plateau is a durability signal.

The longest follow-up data come from the Jerosch PMCF study, which recorded a mean IKDC gain of 32.4 points at 12 months that was sustained — and slightly increased — at 3-year follow-up, with patients reaching a mean IKDC of 80. On a scale where 100 represents full function, a score of 80 reflects a clinically meaningful recovery from a pre-treatment baseline that typically indicates significant functional impairment.

MOCART scores — what MRI shows about the repair tissue

MOCART 2.0 is a 0–100 MRI scale that evaluates the structural quality of cartilage repair tissue — not how the knee feels. It scores defect filling volume (in 25% increments), surface contour, integration with adjacent native cartilage, tissue signal intensity, and subchondral changes. An interclass correlation coefficient (ICC) of 0.875 — measured across 114 patients treated with multiple repair techniques — confirms it is a reproducible instrument between readers.

In ChondroFiller knee studies, 12-month MOCART values cluster between 81.6 and 84.3: the excellent structural range, reflecting more than 80% defect filling with good cartilage integration. The maturation data are equally telling. One key study recorded a mean MOCART of 65.3 at four weeks rising to 81.6 at one year — a 16-point gain as recruited cells deposit extracellular matrix and the scaffold consolidates. A mid-60s score shortly after treatment is therefore an expected early-stage finding; the one-year value is the meaningful structural endpoint.

A 2025 study of 86 tibiofemoral cartilage repair patients identified a practical landmark: a MOCART 2.0 score of 60 or above at one year is associated with higher IKDC, Lysholm, and KOOS scores and slower OA progression at follow-up. ROC analysis confirmed the clinically meaningful cut-off at 56–61 points. ChondroFiller's 12-month values of 81–84 sit comfortably above this level, consistent with the functional gains the IKDC data reflect.

Part of the reason fill scores are strong relates to formulation. Compared with multilayered or single-layered solid scaffolds, gel-based injectable scaffolds had substantially fewer cases of incomplete defect filling in a meta-analysis of 876 patients — a hydrogel that sets in situ can conform fully to the irregular contour of a real cartilage defect, leaving fewer unfilled margins. Because the gel is initially soft before stable integration is established, post-treatment protocols typically restrict full weight-bearing until the scaffold has consolidated.

Why a good MRI score and a good functional score don't always go together

The finding is counterintuitive but well-established. A 2021 systematic review examining MOCART's relationship with IKDC (P=0.9), Lysholm (P=0.2), Tegner Activity Scale (P=0.2), VAS pain (P=0.07), and failure or revision rates found no statistically significant association between MRI appearance and patient-reported outcomes in knee cartilage repair. A higher MOCART score, in other words, does not reliably predict a higher IKDC.

This does not make MOCART uninformative; it makes MOCART a different kind of information. The score describes what the repair tissue looks like on MRI — its volume, surface contour, integration, and signal intensity. IKDC describes how the knee functions in daily life and sport. These are genuinely distinct questions, and factors outside the repair site — residual muscle weakness, incomplete rehabilitation, adjacent joint pathology, or altered load distribution — can suppress IKDC even when cartilage integration looks structurally sound on imaging.

The reverse is equally possible. A patient may report significant functional gains while the repair tissue is still maturing on MRI — precisely the pattern the early-stage MOCART trajectory illustrates, with scores continuing to climb well into the first year as the scaffold consolidates.

For ChondroFiller, what the evidence shows across studies is convergence rather than divergence: the structural and functional scores move in the same favourable direction over the same timeframe. That alignment is reassuring precisely because the systematic-review evidence establishes it cannot be taken for granted. Interpreting either score in isolation risks missing part of the picture; read together, they offer a more complete account of how the knee is responding.

Who is likely to benefit and what to expect realistically

Patients most likely to see meaningful benefit are those with a focal articular cartilage defect in an otherwise healthy knee — minimal background osteoarthritis, preserved joint alignment, and a defect suited to scaffold filling rather than widespread joint degeneration. Hip cohort data offer the most directly relevant signal here: in the absence of knee-specific OA-grade stratification data, the finding that patients with Tönnis grade 2–3 osteoarthritis fared poorly is the strongest available comparator, and suggests advanced background OA is likely to limit outcomes in the knee as well.

On timing, functional and structural recovery move in the same direction but on different schedules. IKDC gains appear to plateau at a high, durable level by six months and are sustained at 12 months without significant further change. MOCART values, by contrast, continue rising through the first year — a four-week scan captures early scaffold stabilisation, not mature repair tissue, and should not be read as the definitive structural verdict.

Current evidence — drawn from smaller, often manufacturer-associated studies — is consistent and encouraging, but larger randomised trials comparing ChondroFiller directly to ACI or osteochondral autograft over two or more years are still needed to situate these outcomes in the broader cartilage-repair literature.

What the data as a whole show is that the approximately 30-point IKDC gain and 12-month MOCART values of 81–84 represent convergent structural and functional evidence of repair in well-selected patients — a picture that only becomes fully visible when both scores are read together rather than in isolation. That is the practical take-home the preceding five sections have built towards. For a clinical assessment of whether your defect profile and joint status make you a suitable candidate, Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Book an assessment at lincolnshireknee.co.uk.

1. [1] Reliability of the MOCART 2.0 knee score for different cartilage repair techniques — a retrospective observational study. (2021). https://doi.org/10.1007/s00330-021-07688-1 https://doi.org/10.1007/s00330-021-07688-1
2. [2] The MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) 2.0 Knee Score and Atlas. (2019). https://doi.org/10.1177/1947603519865308 https://doi.org/10.1177/1947603519865308
3. [3] MOCART 2.0 score of 60 or greater measured at 1 year post-operatively predicts favourable clinical outcomes after surgical repair of tibiofemoral cartilage lesions. (2025). https://doi.org/10.1002/ksa.70086 https://doi.org/10.1002/ksa.70086
4. [4] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
5. [5] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
6. [6] Reliability of the MOCART score: a systematic review. (2021). https://doi.org/10.1186/s10195-021-00603-w https://doi.org/10.1186/s10195-021-00603-w
7. [7] Implantation of ChondroFiller Liquid® as a scaffold material for the treatment of chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
8. [8] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
9. [9] Does the Choice of Acellular Scaffold and Augmentation With Bone Marrow Aspirate Concentrate Affect Short-term Outcomes in Cartilage Repair? A Systematic Review and Meta-analysis. (2022). https://doi.org/10.1177/03635465211069565 https://doi.org/10.1177/03635465211069565
10. [10] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z